Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 10/03/2024
|
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
- CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda's oncology research and development efforts. After an initial collaboration that leveraged Tempus' de-identified multimodal datasets, this new agreement will expand upon.
- 09/26/2024
|
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and that has progressed after chem.
- 09/24/2024
|
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company's ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda's focus on tackling systemic disparities and supporting local leadership in strengthening health infrastructure, empowering h.
- 09/18/2024
|
TAK vs. STVN: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
- 09/17/2024
|
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 09/17/2024
|
US allows increased production of Takeda's ADHD drug to address shortage
- The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the medicine's ongoing shortage in the United States.
- 09/04/2024
|
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
- Monday, the FDA approved Ascendis Pharma A/S' ASND Yorvipath (palopegteriparatide; developed as TransCon PTH) for hypoparathyroidism in adults.
- 08/12/2024
|
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
- Takeda Pharmaceutical Co Ltd TAK stock is trading higher on Wednesday. Earlier today, the European Commission approved Takeda's Adzynma (recombinant ADAMTS13) for treating ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP).
- 08/07/2024
|
Takeda Pharmaceutical Company Limited (TAK) Q1 2025 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q1 2025 Results Conference Call July 31, 2024 6:30 AM ET Company Participants Christopher O'Reilly - Head-Investor Relations Christophe Weber - President and Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President of R&D Julie Kim - President of U.S. Business Unit Conference Call Participants Hiroyuki Matsubara - Nomura Securities Steve Barker - Jefferies Shinichiro Muraoka - Morgan Stanley Mike Nedelcovych - Cowen Seiji Wakao - JPMorgan Chase & Co Tony Ren - Macquarie Kasumi Haruta - UBS Investment Bank Hidemaru Yamaguchi - Citigroup Miki Sogi Sanford - Bernstein Christopher O'Reilly Thank you very much for taking time out of your very busy schedule to join us for this first quarter earnings call by Takeda for FY ‘24. I'm the master of ceremony today.
- 08/02/2024
|
BostonGene Announces Partnership with Takeda to Evaluate Immunotherapies Using AI-Powered Molecular Profiling
- WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, announced that it will collaborate with Takeda on immuno-oncology focused research studies. This partnership aims to identify key molecular drivers and predictive markers for treatment efficacy and adverse effects with the primary goal of advancing clinical solutions and improving patient outcomes. Takeda will leverage BostonGene's AI-powered multiomic.
- 08/01/2024
|
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
- OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2024 (period ended June 30, 2024), with continued momentum in its Growth & Launch Products driving Core growth at CER and more than offsetting revenue impact resulting from significant losses of exclusivity that occurred in the previous fiscal year. The strong performance of Takeda's Growth and Launch Product portfolio, which grew 17.8% at CER and represented 46%.
- 07/31/2024
|
3 Biotech Stocks to Buy on the Dip: July 2024
- The biotechnology sector doesn't need to rizz up investors, as the kids like to say. Unless the human desire to find solutions for vexing conditions and diseases somehow goes away in a dystopian paradigm, the ecosystem is safe.
- 07/29/2024
|
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
- AC Immune SA's Takeda Pharmaceutical Company partnership brought in an upfront payment of $100 million, with the potential to earn up to $2.1 billion in milestone payments. Interim safety and immunogenicity data from the phase 2 ABATE trial using ACI-24.060 for the treatment of Down Syndrome patients with AD, expected 2nd half of 2024. The global Alzheimer's therapeutics market size is expected to surpass $8.18 billion by 2032.
- 07/26/2024
|
Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline
- Takeda Pharmaceutical Company Limited showed signs of improvement despite revenue declines in oncology and neurosciences, thanks to gains in gastrointestinal and inflammation sectors and strategic leadership changes. The company's “returning to growth program” aims to increase operating margins by 100-250 basis points annually from 2025 onwards. Despite a challenging FY2023 with a significant net profit decline, Takeda expects its AI-powered returning to growth program to improve financial stability and shareholder returns by 2025.
- 07/19/2024
|
3 Biotech Stocks For The Second Half Of 2024
- The small biotech sector has badly underperformed the major market indices so far in 2024.
- 06/27/2024
|
Takeda Announces New Assignments of Directors
- OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The.
- 06/26/2024
|
Takeda To Keep Pushing for China Biotech Partnership
- Takeda Pharmaceutical will continue efforts to forge partnerships with Chinese biotech companies even with some tensions between US and China. Speaking exclusively to Bloomberg, CEO Christophe Weber said the recent US Congress effort to limit Chinese biotech's access to American market would have limited impact on Takeda's business with China.
- 06/25/2024
|
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies.4 LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.1 “We are pleased by the approval.
- 06/24/2024
|
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an inc.
- 06/22/2024
|
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to.
- 06/21/2024
|
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India
- Japan's Takeda Pharmaceutical gave India's Sun Pharmaceutical and Cipla the rights to commercialize gastrointestinal drug Vonoprazan in the country.
- 06/21/2024
|
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
- ROCKVILLE, Md. and SUZHOU, China , June 20, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the agreed equity investment by Takeda has been closed on June 20, 2024, with all proceeds already received.
- 06/20/2024
|
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Results showed favorable long-term safety and tolerability of HYQVIA, and a low relapse rate, supporting its use as maintenance.
- 06/18/2024
|
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
- Monday, Takeda Pharmaceutical Co Ltd TAK announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).
- 06/17/2024
|
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced topline data from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase 3 study that evaluated soticlestat (TAK-935) plus standard of care versus placebo plus standard of care in patients with refractory Dravet syndrome (DS).1 Soticlestat narrowly missed the primary endpoint of reduction from baseline in convulsive seizure frequency as compared to place.
- 06/17/2024
|
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
- Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas. Ascentage Pharma to receive an option payment of 100 million USD upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion USD, and double-digit royalties on annual sales Additionally, Takeda will purchase a minority interest in Ascentage Pharma ROCKVILLE, Md.
- 06/14/2024
|
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license global rights to develop and comm.
- 06/14/2024
|
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that it has expanded its partnership with Partners In Health (PIH), an international nonprofit organization, to support a new initiative with PIH that aims to address social determinants of health and improve access to care within communities across Massachusetts. This builds on Takeda's existing global partnership with PIH that has been in place since 2017. Takeda's work with PIH has focused on strengthening the capacity o.
- 06/11/2024
|
Celiac Disease Market and Epidemiology Analysis 2018-2034 with Detailed Profiles of Marketed and Pipeline Drugs, Including KAN-101 (Kanyos Bio) and TIMP-GLIA/TAK 101 (Takeda)
- Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Celiac Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering. The 7 major Celiac disease markets reached a value of US$ 584.9 Million in 2023. Looking forward, the 7MM are expected to reach US$ 1,362.1 Million by 2034, exhibiting a growth rate (CAGR) of 9.85% during 2023-2034. The increasing incidences of inherited chromosomal disorders on account of gene mutations, mainly HLA-DQ2 and HLA-DQ8, are primarily driving the celiac disease market. In addition to this, the rising prevalence of several associated risk factors, such as gastrointestinal infections, type 1 diabetes, autoimmune thyroid disease, alterations in the composition and diversity of gut bacteria, etc., is creating a positive outlook for the market. Moreover, the easy utilization of enzyme supplements, including lactase and alpha-galactosidase, to improve digestion and reduce symptoms of bloating and gas is also propelling the market growth.
- 06/07/2024
|
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. TAK-861 is an investigational oral orexin receptor 2 (OX2R) agonist and, based on the results, has the potential to provide transformative efficacy in addressing the overall.
- 06/03/2024
|
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
- OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting (LBA7000) and at the 29th European Hematology Association (EHA) Annual Meeting (S225).
- 06/01/2024
|
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP. The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for.
- 05/31/2024
|
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill. Takeda's presentations will span across a range of cancers, including colorectal, lung, lymphoma, multiple myeloma and leukemia and feature both clinical and real-world data generated to optimize treatm.
- 05/14/2024
|
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
- OSAKA, Japan & CAMBRIDGE, Mass & LAUSANNE, Switzerland--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer's disease. ACI-24.060 is an anti-Abeta active immunotherapy candidate designed to induce a robust antibody response against the toxic forms of Abeta believed to.
- 05/13/2024
|
Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited (NYSE:TAK ) Fiscal Year 2023 Earnings Conference Call May 9, 2024 6:00 AM ET Company Participants Christopher O'Reilly – Head-Investor Relations Christophe Weber – President and Chief Executive Officer Andy Plump – President of R&D Milano Furuta – Chief Financial Officer Ramona Sequeira – President of Global Portfolio Division Julie Kim – President of U.S. Business Unit Giles Platford – President, PDT Business Unit Conference Call Participants Steve Barker – Jefferies Hidemaru Yamaguchi – Citi Mike Nedelcovych – Cowen Shinichiro Muraoka – Morgan Stanley Tony Ren – Macquarie Hiroyuki Matsubara – Nomura Securities Kasumi Haruta – UBS Geoff Watson – SMBC Nikko Securities Christopher O'Reilly Thank you very much for your participation in the Conference Call for the Financial Results for Fiscal Year 2023 of Takeda Pharmaceutical Company Limited. My name is O'Reilly, Head of Investor Relations.
- 05/10/2024
|
Takeda Pharmaceuticals earnings: profits, EPS down over 50% in Q4 financial results
- Japanese pharmaceutical titan Takeda (NYSE: TAK/TSE: 4502) today announced their financial results for Q4 and the full fiscal year of 2023. The company described it in a press release as “a year of significant loss-of-exclusivity impact”, a grim picture which was backed up by the company's financials.
- 05/09/2024
|
Japan's Takeda Pharma says full-year profit slumps 56%
- Japan's Takeda Pharmaceutical said full-year earnings slumped by 56% as the company focused on rebuilding its drug pipeline to make up for the loss of patent protection for major sellers.
- 05/09/2024
|
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
- Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 04/29/2024
|
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
- Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 04/26/2024
|
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when.
- 04/26/2024
|
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
- Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 04/25/2024
|
TAK or CTLT: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks presents investors with the better value opportunity right now?
- 04/25/2024
|
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 04/25/2024
|
New Strong Buy Stocks for April 25th
- TAK, TXO, PEPG, ERO and RMNI have been added to the Zacks Rank #1 (Strong Buy) List on April 25, 2024.
- 04/25/2024
|
Best Value Stocks to Buy for April 25th
- RMNI, TAK and ASBFY made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 25, 2024.
- 04/25/2024
|
Best Income Stocks to Buy for April 25th
- CIB, TAK and ASBFY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 25, 2024.
- 04/25/2024
|
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
- SAVITRI™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Statistically Significant Reduction in MADRS Score at Day 56 NBI-1065845 Was Generally Well-Tolerated SAN DIEGO , April 23, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD).
- 04/23/2024
|
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
- TOKYO , April 22, 2024 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), and Sumitomo Mitsui Banking Corporation (President & CEO: Akihiro Fukutome, "SMBC") today announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company. The new company will be dedicated to the incubation*1 of early drug discovery programs, primarily originating from Japan and toward the creation of innovative therapeutics.
- 04/22/2024
|
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD) after induction therapy with intravenous (IV) ENTYVIO.1 The subcutaneous administration of ENTYVIO was also approved by FDA in September 2023 for the maintenance treatment of adults with moderately.
- 04/18/2024
|
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its FY2023 U.S. Corporate Social Responsibility (CSR) program. To create greater impact and foster equity in under-resourced communities, the company is focusing its philanthropic efforts on the two areas of Food is Health and Building STEM (Science, Technology, Engineering and Math) Foundations and.
- 04/08/2024
|
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
- Takeda's 'In Their Shoes' initiative illuminates the daily struggles of IBD patients in the UAE, fostering empathy and understanding among participants. DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE.
- 03/27/2024
|
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Furuta, currently president of the Japan Pharma Business Unit (JPBU), will succeed Mr. Constantine Saroukos as chief financial officer (CFO) effective April 1, 2024. Takeda will propose Mr. Furuta as a new.
- 03/26/2024
|
2 More Potential Biotech Buyout Targets
- M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.
- 03/25/2024
|
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
- Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy, RNA editing, gene therapy, and RNA interference.
- 03/14/2024
|
Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?
- Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 03/11/2024
|
TAK or STVN: Which Is the Better Value Stock Right Now?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
- 03/11/2024
|
Japan's Takeda partners with India's Biological E. to boost dengue vaccine production
- Japan's Takeda Pharmaceutical will scale up production of its dengue vaccine Qdenga through a partnership with Indian vaccines maker Biological E., the companies said on Tuesday.
- 02/27/2024
|
US FDA approves Takeda's therapy for allergic inflammation in esophagus
- Drugmaker Takeda said on Monday the U.S. Food and Drug Administration has approved its therapy for a type of allergic inflammation of the esophagus, making it the first oral treatment for the condition.
- 02/12/2024
|
Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript
- 02/02/2024
|
3 Stocks to Buy to Benefit From the Booming Sleep Industry
- Google “How important is sleep?” and you get three billion results.
- 01/23/2024
|
One Ultra-Cheap High-Yield Dividend Stock to Buy
- Takeda Pharmaceutical is one of the top pharma companies in the world. It has a broad mix of products in its portfolio, which can provide investors with some stability.
- 12/22/2023
|
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 12/07/2023
|
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 11/17/2023
|
US FDA approves Takeda's blood disorder therapy
- The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical's therapy to treat a rare genetic blood disorder in adult and pediatric patients.
- 11/09/2023
|
Takeda says FDA approves its treatment for colorectal cancer
- Pharmaceutical company Takeda 4502, +0.29% said Wednesday that the U.S. Food and Drug Administration approved Fruzaqla as a treatment for certain patients with colorectal cancer.
- 11/08/2023
|
TAK vs. STVN: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
- 10/27/2023
|
Takeda Pharmaceutical Company Limited (TAK) Q2 2023 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2023 Earnings Conference Call October 26, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Head of Investor Relations Christophe Weber - President and Chief Executive Officer Andy Plump - President of R&D Costa Saroukos - Chief Financial Officer Julie Kim - President, U.S. Business Unit and U.S. Country Head Ramona Sequeira - President, Global Portfolio Division Conference Call Participants Hidemaru Yamaguchi - Citigroup Shinichiro Muraoka - Morgan Stanley Seiji Wakao - J.P. Morgan Steve Barker - Jefferies Kazuaki Hashiguchi - Daiwa Securities Michael Nedelcovych - TD Cowen Miki Sogi - Bernstein Akinori Ueda - Goldman Sachs Christopher O'Reilly Thank you very much for joining us out of your busy schedule today for the earnings call for Second Quarter Fiscal 2023 with Takeda Pharmaceutical Company Limited.
- 10/27/2023
|
Japan's Takeda slashes full-year profit forecast on drug pipeline impairments
- Japan's biggest drugmaker Takeda Pharmaceutical on Thursday slashed its full-year profit forecast by 36% as it contends with disappointments in its development pipeline and the loss of patent protection on key products.
- 10/26/2023
|
Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play
- High yields may seem attractive, however, homework can go a long way. Takeda's Phase 3 ADMIRE CD II study & Phase 3 EXCLAIM-2 trial both failed to meet key endpoints, thus impacting the company's FY23 outlook. When the company reports Q2 earnings on October 26, don't be surprised if FY23 forecasts are revised downward.
- 10/24/2023
|
Takeda trial for Crohn's Perianal Fistulas treatment misses primary endpoint
- Takeda 4502, -0.33% said Tuesday its trial of darvadstrocel in the treatment of complex Crohn's Perianal Fistulas didn't meet its primary endpoint based on topline data.
- 10/17/2023
|
Takeda's dengue vaccine gets WHO group's recommendation
- American depositary receipts of Takeda Pharmaceutical Co. 4502, -1.79% TAK, -2.16% rose more than 1% in the extended session Tuesday after the Japan-based company said its dengue vaccine got the recommendation from an immunizations advisory board with the World Health Organization. The WHO will consider the recommendation in the coming weeks, the company said.
- 10/03/2023
|
Takeda announces voluntary withdrawal of lung cancer therapy
- Takeda Pharmaceutical said on Monday it would be working with the U.S. health regulator towards a voluntary withdrawal of its lung cancer therapy in the country, after it failed to meet the main goal in a late-stage study.
- 10/02/2023
|
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
- Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
- 08/31/2023
|
ImmunoGen stock jumps after licensing deal with Japan's Takeda Pharmaceutical
- Shares of ImmunoGen Inc. IMGN, +1.45% jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with Takeda Pharmaceutical Co. Ltd. TAK, +0.59% 4502, +0.52% to commercialize its Elahere ovarian cancer treatment in Japan.
- 08/28/2023
|
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 08/25/2023
|
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
- One of these high-yield pharma stocks stands out as a better buy right now.
- 08/24/2023
|
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now
- High-yield dividend stocks can be great additions to a long-term-oriented portfolio. Takeda Pharmaceutical and AT&T screen as two of the most attractive buys in the high-yield space right now.
- 08/23/2023
|
Takeda says it has 40 clinical-stage medicines in the pipeline
- Christophe Weber, CEO of Takeda, says there are some setbacks in research and development, but most of those drugs should fuel the company's growth in the future.
- 07/28/2023
|
Takeda withdraws US application for dengue vaccine candidate
- Takeda Pharmaceutical Co said on Tuesday it was voluntarily withdrawing its application for its dengue vaccine candidate, following discussions with the U.S. health regulator.
- 07/11/2023
|
Takeda: Upside Case Strengthening, Looking To 15x Earnings
- Takeda Pharmaceutical's stock has appreciated 10% since December, with economic and fundamental catalysts supporting a buy rating. TAK has shown strong growth in revenue and operating capital as well as promise in its pipeline and geographic diversification. A valuation of $41.8 per share is potentially warranted, with a reiterated buy rating.
- 06/21/2023
|
Takeda Pharmaceutical Company Limited (TAK) Q4 2022 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2022 Results Conference Call May 11, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Global Head of IR & Global Finance Christophe Weber - President, CEO & Representative Director Andrew Plump - President of Research & Development and Representative Director Constantine Saroukos - CFO & Representative Director Julie Kim - President of the U.S. Business Unit & U.S. Country Head Giles Platford - President of the Plasma-Derived Therapies Business Unit Ramona Sequeira - President of Global Portfolio Division Conference Call Participants Yamaguchi-san - Citigroup Tony Ren - Macquarie Mamegano-san - BofA Securities Muraoka-san - Morgan Stanley Michael Nedelcovych - TD Cowen Miki Sogi - Bernstein Christopher O'Reilly Thank you very much for joining FY 2022 earnings announcement of Takeda. I will serve as MC, Head of IR.
- 05/11/2023
|
Why Do We Keep Buying Takeda Pharmaceutical Shares
- Sales of Takhzyro amounted to 44.1 billion Japanese yen in the 3rd quarter of 2022, an increase of 42.7% from the previous year. Takeda Pharmaceutical's revenue was $8,354 million in Q3 2022, showing phenomenal growth both year-on-year and quarter-on-quarter.
- 04/03/2023
|
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 03/30/2023
|
Price Growth & Yield: For That Magical Combo, Leave the U.S.
- It's not often you find one stock with sustained price growth and solid dividend yield, but three foreign stocks, Takeda Pharmaceutical Co., Ltd. (NYSE: TAK), United Microelectronics Corp. (NYSE: UMC) and Coca-Cola FEMSA SAB de CV (NYSE: KOF) are showing that magical combination.
- 03/21/2023
|
Big Stocks Making New Highs Despite Everything
- Interest rates may be headed higher and regional banks may be in trouble but that hasn't stopped just a few stocks from hitting new highs.
- 03/18/2023
|
Takeda: Pipeline Expanding But Growth Worries Persist
- Takeda's late-stage pipeline is impressive with many candidates boasting very strong fundamentals. Technically though, shares are now coming up against significant overhead resistance.
- 03/16/2023
|
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 03/09/2023
|
Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q3 2023 Earnings Conference Call February 2, 2023 5:30 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Andy Plump - President, R&D Costa Saroukos - Chief Financial Officer Ramona Sequeira - President, Global Portfolio Division Conference Call Participants Hidemaru Yamaguchi - Citigroup Motoya Koutani - Nomura Securities Seiji Wakao - JPMorgan Shinichiro Muraoka - Morgan Stanley Christopher O'Reilly Thank you for taking time out of your very busy schedule to join us for the FY ‘22 Q3 Earnings Announcement by Takeda. My name is O'Reilly, Head of IR.
- 02/02/2023
|
7 Sorry Dividend Stocks to Sell in February Before It's Too Late
- When it comes to dividend stocks, the consensus is that the higher the yield, the better. High dividend yields can often be an indication that something is wrong.
- 01/30/2023
|
Takeda inks deal with Hutchmed for up to $1.1 billion
- Takeda Pharmaceutical Co. Ltd. TAK, +0.43% 4502, +0.65% said Monday that it will acquire Hutchmed's HCM, +1.46% 13, +1.10% experimental cancer treatment outside mainland China, Hong Kong and Macau, with plans to develop and commercialize fruquintinib.
- 01/23/2023
|
Hutchmed shares jump on US$1.13bn Takeda deal
- Shares in Hutchmed (China) Ltd jumped 6.5% after it announced a licensing deal with Takeda Pharmaceutical worth US$1.13bn. With an upfront payment of US$400mln plus milestones, the agreement allows the Japanese group to develop Hutchmed's cancer treatment, fruquintinib, outside China.
- 01/23/2023
|
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
- Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.
- 12/30/2022
|
Takeda: Late-Stage Pipeline Catalysts Approaching, But Vyvanse Patent Expiration Looms
- Entyvio is Takeda's key growth driver, and the management expects it to offset the effect of Vyvanse's patent expiration next year. The company aims to improve margins on its plasma-derived therapies (PDT) and is already seeing some signs in this regard.
- 12/13/2022
|
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
- OSAKA, Japan & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Takeda ( TSE:4502/NYSE:TAK ) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) Annual Meeting being held December 10-13, 2022 in New Orleans. Takeda's latest research focuses on improving long-term outcomes for patients with hematologic diseases.
- 12/09/2022
|
Takeda: Momentum Building Around Core Offerings, Rate Buy
- Strong top-line growth exhibited in FY22. Building regulatory and clinical momentum around its core offerings, with the bulk of the portfolio up double digits this year.
- 12/07/2022
|
2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade
- Is now the time to load up on these high-yielding investments?
- 11/16/2022
|
Takeda Pharmaceutical Company Limited (TAK) Q2 2022 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2022 Results Conference Call October 27, 2022 5:30 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - President and CEO Andrew Plump - President, R&D Costa Saroukos - CFO Ramona Sequeira - President, Global Portfolio Division Teresa Bitetti - President, Global Oncology Business Unit Julie Kim - President, US Business Unit Giles Platford - President, Plasma-Derived Therapies Business Unit Masato Iwasaki - Representative Director, Japan General Affairs Conference Call Participants Hidemaru Yamaguchi - Citi Stacy Ku - Cowen Motoya Koutani - Nomura Securities Shinichiro Muraoka - Morgan Stanley Seiji Wakao - J.P. Morgan Fumiyoshi Sakai - Credit Suisse Securities Akinori Ueda - Goldman Sachs Securities Naomi Kumagai - Mitsubishi UFJ Morgan Stanley Hiroaki Hashimoto - Nikkei BP Ayako Iwamuro Thank you very much for taking time out of your busy schedule to join us today for Takeda's Financial Results Webinar for the Second Quarter of Fiscal Year 2022.
- 10/27/2022
|
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
- Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
- 10/20/2022
|
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
- These stocks all pay far higher than the S&P 500 average dividend yield of 1.8%.
- 10/19/2022
|
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
- TAK vs. ZTS: Which Stock Is the Better Value Option?
- 09/21/2022
|
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 09/15/2022
|
Got $5,000? These 2 Dividend Stocks Haven't Been This Cheap in Years
- These stocks both yield more than three times the S&P 500 average.
- 09/14/2022
|
Takeda: A Lot To Like
- Takeda has a stable, reliable core drug portfolio with some new product areas showing promise. Their global reach puts them on par with western pharmaceutical companies, but also presents a headwind for expenses and currency exchange rates.
- 09/13/2022
|
Takeda: The Current Price Makes No Sense
- Takeda has a dividend yield of 5.26%. It represents only 28% of free cash flow. Takeda is undervalued by nearly 70%.
- 09/08/2022
|
Takeda: Benefits From A Falling Yen, But Shares Stuck In A Downtrend
- The USD-JPY cross has surged to fresh 24-year highs, up more than 30% YoY. The currency move is a benefit from Takeda Pharma, but the stock has not performed well in 2022 despite boasting a big dividend.
- 09/07/2022
|
TAK or ZTS: Which Is the Better Value Stock Right Now?
- TAK vs. ZTS: Which Stock Is the Better Value Option?
- 09/05/2022
|
TAK vs. ZTS: Which Stock Is the Better Value Option?
- TAK vs. ZTS: Which Stock Is the Better Value Option?
- 08/19/2022
|
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
- TAK vs. ZTS: Which Stock Is the Better Value Option?
- 08/03/2022
|
Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q1 2022 Results - Earnings Call Transcript
- Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q1 2022 Results Conference Call July 28, 2022 6:00 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - President and CEO Andy Plump - President, R&D Costa Saroukos - CFO Masato Iwasaki - Japan General Affairs Conference Call Participants Hidemaru Yamaguchi - Citi Motoya Koutani - Nomura Securities Seiji Wakao - J.P. Morgan Securities Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - Credit Suisse Securities Akinori Ueda - Goldman Sachs Ayako Iwamuro Good evening everybody or good morning everybody.
- 07/29/2022
|
Takeda sees quarterly profit drop 39% after last year's one-time gains
- Japan's Takeda Pharmaceutical Co said on Thursday first-quarter profit slumped 39% percent from a year earlier, when earnings had been boosted by the sale of its diabetes drug portfolio.
- 07/28/2022
|
What's Winning in 2022? 3 Stocks That Are Doing Fine
- Immunocore, Axsome Therapeutics, and Takeda are significantly outperforming the market this year.
- 07/16/2022
|
Biotech Public Offerings at 10-Year Low
- No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerings have sunk to a 10-year low, according to a report from Evaluate.
- 07/11/2022
|
Trial Results Set to Make or Break Small-Cap Pharma Stocks
- One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration approval. If that happens, Jefferies analyst Chris Howerton believes the treatment should have “no issue” topping annual sales of $1 billion, reported BioPharma Dive.
- 07/06/2022
|
Takeda, Nintendo among Japanese firms quietly celebrating weak yen
- Japan's yen is at its weakest in decades and inflicting high costs of imported food and fuel on households and businesses, but also proving to be an unexpected tailwind for multinationals such as pharmaceutical giant Takeda.
- 06/17/2022
|
Takeda Pharmaceutical Vs. Gilead Sciences: Who Is The Dividend King?
- Takeda's total debt was $35,698.6 million, down 22.1% from the previous year. Takeda Pharmaceutical has a dividend yield of 5.15%, and Gilead Sciences has a dividend yield of 4.53%.
- 06/15/2022
|
Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes
- Improving your investing process tends to have high returns.
- 06/11/2022
|
Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond
- These three healthcare stocks should hold their value for years.
- 05/26/2022
|
Takeda Pharmaceutical: A Bright Decade Ahead
- Takeda Pharmaceutical will be able to deliver stellar growth during the next decade. China and emerging markets will be a key driver of growth.
- 05/23/2022
|
Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q4 2022 Results - Earnings Call Transcript
- Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2022 Earnings Conference Call May 11, 2022 6:00 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - CEO Andy Plump - R&D President Constantine Saroukos - CFO Giles Platford - President of the PDT Business Unit Julie Kim - President, U.S. Business Unit & U.S. Country Head Ramona Sequeira - President, Global Portfolio Division Masato Iwasaki - Representative Director Conference Call Participants Shinichiro Muraoka - Morgan Stanley Stephen Barker - Jefferies Seiji Wakao - JPMorgan Chase & Co Stacy Ku - Cowen and Company Fumiyoshi Sakai - Crédit Suisse Hidemaru Yamaguchi - Citigroup Ayako Iwamuro Thank you very much for your participation in Fiscal Year 2021 Earnings webinar of Takeda Pharmaceuticals. I am Ayako Iwamuro, IR of Takeda Pharmaceuticals.
- 05/12/2022
|
Japan's Takeda Pharma says full-year profit slid 9.5%
- Takeda Pharmaceutical Co said on Wednesday that 12-month operating profit slid 9.5% from the previous year.
- 05/11/2022
|
3 Japanese Stocks to Diversify Your Portfolio
- Japan has the world's third-largest economy, which has started to rebound from the pandemic. The Japanese economy expanded at a 5.4% annualized rate in the fourth quarter of 2021.
- 03/07/2022
|
Takeda Pharma: A Japanese Dividend Powerhouse
- Takeda Pharmaceutical ( TAK , Financial) is Japan's largest R&D-focused biopharma company. Founded in 1781, this is an established company with a global presence.
- 03/07/2022
|
The Best Russell 2000 Stocks to Buy Before they Rebound
- Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.
- 02/15/2022
|
Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q3 2022 Results - Earnings Call Transcript
- Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q3 2022 Results - Earnings Call Transcript
- 02/03/2022
|
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
- The FDA has approved Takeda Pharmaceutical Co Ltd's TAK Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in Type 3 von Willebrand disease (VWD) receiving on-demand therapy. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.
- 01/31/2022
|
2 Dirt-Cheap Value Stocks to Buy Now
- These two dividend-paying pharma stocks ought to be top performers in 2022.
- 01/29/2022
|
T. Rowe Price Japan Dumps Takeda Holding in 4th Quarter
- The T. Rowe Price Japan Fund (Trades, Portfolio), part of Baltimore-based T.
- 01/21/2022
|
3 Healthcare Stocks With High Dividends
- Looking for a healthcare stock that will pay you to own it? Here are three suggestions.
- 01/21/2022
|
Phathom Pharmaceuticals: Undiscovered Gem
- Phathom Pharmaceuticals: Undiscovered Gem
- 01/20/2022
|
4 'Below Book Value' Stocks
- These four stocks are all trading below their book value, making it likely that their names are showing up on the value screens of large institutional investors. Since each one trades on the New York Stock Exchange, plenty of information is available for those who want to go into depth on them in order to determine whether they could be good investments.
- 12/23/2021
|
FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study
- Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral suspension) for eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus. The CRL indicates the FDA has completed its review of the TAK-721 NDA and determined that it cannot be approved in its present form.
- 12/22/2021
|
Takeda Pharmaceutical: Underappreciated Potential
- ENTYVIO's sales totaled about ¥130.5 billion in Q2 2021, up 4.1% quarter-on-quarter and 23.5% Q1 2020. Revenue for the company's key 14 medicines increased by 23.9% in the second quarter of 2021 compared to the previous quarter.
- 12/19/2021
|
3 Stocks Trading With Low Price-to-Free-Cash-Flow Ratios
- If you want to increase your likelihood to discover value opportunities, one method is to screen the market for stocks with trailing 12-month price-to-free-cash-flow ratios lower than that of the S&P 500 Index, which stands at around 14.48 as of the writing of this article.
- 12/08/2021
|
Cathie Wood's ARK Invest Sells Nearly 850,000 Shares of Takeda Pharma
- One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 850,000 shares of Takeda Pharmaceutical Co.
- 12/08/2021
|
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
- These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared first on InvestorPlace.
- 12/07/2021
|
Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval
- The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.
- 11/25/2021
|
Takeda's Maribavir Scores FDA Approval For Post-Transplant CMV Infection
- The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Livtencity (maribavir) for a common type of viral infection occurring in patients after organ transplant. The infection is caused by a type of herpes virus called cytomegalovirus (CMV).
- 11/24/2021
|
3 Low Price-Book Ratio Stocks
- Screening for stocks with market capitalizations exceeding $10 billion and price-book ratios below 1.5 could help value investors to discover more opportunities among U.S.-listed equities. Thus, value investors may want to consider the following stocks, as they match the criteria above and are recommended by Wall Street.
- 11/18/2021
|
Cathie Wood's ARK Invest Sells Over 690,000 Shares of Takeda Pharma
- One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 690,000 shares of Takeda Pharmaceutical Co.
- 11/17/2021
|
Takeda Is Dirty Cheap: Great Opportunities Lie Ahead
- Takeda owns a very large portfolio of major drugs and an even larger drug pipeline: the present and the future look secured. The stock has never been so cheap: that's why a share repurchase program was initiated.
- 11/12/2021
|
5 Big Dividend Biotech and Pharmaceutical Stocks Have Strong Upside Potential
- For years, one of the most dependable sectors, especially for more conservative investors, was health care, which included the top pharmaceutical and biotech stocks among other holdings.
- 11/01/2021
|
Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q2 2022 Results - Earnings Call Transcript
- Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q2 2022 Results - Earnings Call Transcript
- 10/29/2021
|
Takeda Pharmaceutical: Diversify Your Book With This Excellent Japanese Pharma Play
- Takeda is just off the back of its first half numbers where revenue rose double digits and annual guidance was confirmed.
- 10/28/2021
|
Japan's Takeda half-year profit climbs, announces share buyback
- Japan's Takeda Pharmaceutical Co said on Thursday that its half-year profit rose 61% as the drugmaker tries to wring synergies out of its acquisition of Shire Plc. Operating profit was 346 billion yen ($3.05 billion) in the six months through Sept.
- 10/28/2021
|
Takeda Expands Oncology Pipeline With Cell Therapy Startup Buyout
- Takeda Pharmaceutical Company Limited (NYSE: TAK) announced the exercise of its option to acquire GammaDelta Therapeutics Limited, a T cell startup. A little more than four years ago, Takeda stepped in to help bankroll GammaDelta Therapeutics with a $100 million injection.
- 10/27/2021
|
2 of Sarah Ketterer's Stocks Sink Near 52-Week Lows
- While there are still a couple months left in 2021, some of Sarah Ketterer (Trades, Portfolio)'s holdings are potential buying opportunities currently.
- 10/26/2021
|
Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs
- Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue discovery & research of preclinical programs for central nervous system (CNS) indications over a four-year research term. Under terms of the amendment, Takeda will pay Wave $22.5 million for collaboration-related research and preclinical expenses.
- 10/19/2021
|
Calithera Buys Two Oncology Candidates From Takeda For $45M
- Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK). The transaction terms include a total upfront cash payment to Takeda of $10 million and $35 million in Calithera Series A preferred stock.
- 10/19/2021
|
Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M
- Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system in a deal worth potentially more than $900 million.
- 10/14/2021
|
A new deal with Takeda could mean up to $3.6 billion in milestone payments for Poseida Therapeutics
- Shares of Poseida Therapeutics Inc. PSTX, +1.22% were up 9.6% in premarket trading on Tuesday after the company said it signed a research and licensing agreement with Takeda Pharmaceutical Co. Ltd. 4502, -0.12% to study and commercialize up to eight gene therapies.
- 10/12/2021
|
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients. The committee also voted unanimo
- 10/07/2021
|
Why Takeda Pharmaceutical Stock Is Down More Than 10% Today
- The prescription drugmaker is halting a trial before a scheduled stopping point, suggesting it's too dangerous to expect an approval.
- 10/06/2021
|
BofA Downgrades Takeda On Suspension Narcolepsy Drug Trials
- Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the suspension of the Phase II trials of its narcolepsy drug candidate TAK-994 due to safety issues. Following the suspension of this promising pipeline, the company's growth recovery prospects appear dismal, according to BofA Securities.
- 10/06/2021
|
Takeda Discontinues Two Mid-Stage Narcolepsy Trials
- Takeda Pharmaceutical Company Limited (NYSE: TAK) has suspended dosing and has decided to stop Phase 2 studies evaluating TAK-994, an investigational oral orexin agonist. According to Takeda, TAK 994 was undergoing two Phase 2 trials for narcolepsy Type 1 with cataplexy and narcolepsy Type 2 without cataplexy.
- 10/06/2021
|
Takeda Provides Update on TAK-994 Clinical Program
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist. As an immediate precautionary measure, the company has suspended dosing of patients and has decided to stop both Phase 2 studies early. This allows for the timely interpretation of the benefit /risk profile of TAK-994 and to determine next steps for the progra
- 10/05/2021
|
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
- Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NMEs, were approved in September.
- 10/01/2021
|
Takeda Says 'Human Error' Reason Behind Contaminated Moderna COVID-19 Vaccines
- Takeda Pharmaceutical Co Ltd (NYSE: TAK) blamed "human error" as the cause of metal contaminants found in some batches of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine. The contamination led to the withdrawal of 1.63 million doses of the mRNA shot from Japan in August.
- 10/01/2021
|
‘Human Error' Caused Contamination Of Moderna Vaccines In Japan, Distributor Takeda Says
- An investigation carried out by Moderna and the Spanish manufacturer Rovi found that the issue was caused by incorrect assembly of the vaccine vials
- 10/01/2021
|
Takeda In-Licenses Hunter Syndrome Candidate
- Takeda Pharmaceutical Company Limited (NYSE: TAK) and JCR Pharmaceuticals Co Ltd have announced an exclusive collaboration and license agreement to commercialize JR-141 (pabinafusp alfa) for Hunter syndrome (Mucopolysaccharidosis type II or MPS II). JR-141 is an investigational, next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme.
- 09/30/2021
|
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
- OSAKA, Japan & ASHIYA, Hyogo, Japan--(BUSINESS WIRE)--Takeda and JCR announced an exclusive collaboration and license agreement to commercialize JR-141 for the treatment of Hunter syndrome.
- 09/30/2021
|
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug
- In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in favor of AbbVie. The new ruling found that Takeda is guilty of breach of contract for failing to supply its partner with the prostate cancer drug.
- 09/24/2021
|
Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan
- Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.
- 09/22/2021
|
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the addition of four partnerships to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen health systems and improve access to healthcare for all in developing and emerging countries. As part of an annual decision-making process, Takeda employees worldwide voted to add IntraHealth International, Jhpiego, Pathfinder International
- 09/22/2021
|
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan
- Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for maralixibat in Japan for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). Under the terms of the agreement, Takeda will be responsible for regulatory approval and commercialization of maralixibat in Japan.
- 09/21/2021
|
Takeda's Exkivity Scores FDA Nod As First Oral Therapy For Lung Cancer With EGFR Exon20 Insertion
- The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Exkivity (mobocertinib) for non-small cell lung cancer (NSCLC) settings. The approval comes for adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.
- 09/16/2021
|
Takeda's EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved EXKIVITY (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemo
- 09/15/2021
|
Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO
- Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.
- 09/13/2021
|
Takeda (TAK) Hematology Candidate Fails in Late-Stage Study
- Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.
- 09/03/2021
|
Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study
- Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced topline data from the Phase 3 PANTHER study evaluating pevonedistat in blood cancer indications. The trial did not achieve the pre-defined statistical significance for the primary endpoint of event-free survival (EFS).
- 09/02/2021
|
3 Blue-Chips With 52%-164% Upside According To Wall Street
- 3 Blue-Chips With 52%-164% Upside According To Wall Street
- 09/01/2021
|
Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS). The trial evaluated whether the combination of pevonedistat plus azacitidine as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) an
- 09/01/2021
|
The Partnership Effect: Arrowhead Forges Its Future
- The Partnership Effect: Arrowhead Forges Its Future
- 08/26/2021
|
Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer
- Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received approval for Cabometyx (cabozantinib) in Japan. The approval covers Cabometyx combined with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivi (nivolumab) for unresectable or metastatic renal cell carcinoma (RCC).
- 08/26/2021
|
Takeda: A Pharmaceutical Gem From Japan
- Takeda: A Pharmaceutical Gem From Japan
- 08/23/2021
|
BioLife Plasma Services Opens First All-Electric Plasma Donation Center
- TUKWILA, Wash.--(BUSINESS WIRE)--BioLife Plasma Services Opens First All-Electric Plasma Donation Center
- 08/18/2021
|
Takeda To Lead Finch-Partnered Microbiome IBD Drug
- Finch Therapeutics Group Inc (NASDAQ: FNCH) announced that Takeda Pharmaceutical Company Limited (NYSE: TAK) has elected to take the lead on the development of FIN-524, now known as TAK-524, in ulcerative colitis. When Takeda teamed up with Finch Therapeutics in 2017 on inflammatory bowel disease (IBD), it planned to pick up programs after they'd finished Phase 2 trials.
- 08/10/2021
|
5%-Yielding Takeda Pharma Could Triple In 5 Years
- What if I told you there was a blue chip that was offering a safe 5% yield yet was 45% undervalued? Here are the three reasons why Takeda Pharma might be just the thing you need to enjoy generous yield today and a rich retirement tomorrow.
- 08/07/2021
|
4 Big Pharma Dividend Stocks to Buy as Yields Near 2021 Lows
- It has become the proverbial broken record. Every time it seems like yields on government securities will start trending higher, they roll over again.
- 08/04/2021
|
Takeda Pharmaceutical: 5% Dividend Yield With Bullish Catalysts This Year
- Takeda Pharmaceutical: 5% Dividend Yield With Bullish Catalysts This Year
- 08/03/2021
|
Takeda to record 63 billion yen provision, update Q1 results on Irish tax issue
- Takeda Pharmaceutical Co said on Monday it will record a provision of about 63 billion yen ($574.56 million) in its financial statements for the first quarter to reflect a decision by Ireland's tax appeals body relating to tax assessment received by company's unit on a break fee.
- 08/01/2021
|
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the receipt of a decision by the Irish Tax Appeals Commission on July 30, 2021 (IST) to uphold the Irish Revenue Commissioners' position related to the treatment of a break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc. (“AbbVie”). Shire was acquired by Takeda in January 2019. Takeda intends to challenge this outcome through all available legal means includin
- 08/01/2021
|
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q1 2022 Results - Earnings Call Transcript
- Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q1 2022 Results - Earnings Call Transcript
- 07/31/2021
|
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
- Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines
- 07/30/2021
|
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2021 (period ended June 30, 2021). Based on the solid first-quarter results, the Company also confirmed its fiscal year 2021 management guidance and forecast. Fiscal year 2021 remains a year of inflection with Takeda positioned for topline acceleration and continued pipeline progress, including critical regulatory submission
- 07/30/2021
|
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
- CAMBRIDGE, Mass. & MENLO PARK, Calif.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takeda's norovirus vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development and commercialization rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldw
- 07/29/2021
|
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda's Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)
- CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors. TAK-994 is currently being studied for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1),2 a chronic ne
- 07/28/2021
|
Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders
- 07/20/2021
|
Moderna partners with Takeda, Japanese government on additional 50 million COVID-19 vaccine doses
- Shares of Moderna Inc. rose 1.4% in premarket trading Tuesday, after the biotechnology company said it has partnered with Takeda Pharmaceutical Co. Ltd. and the Ministry of Health, Labour and Welfare of Japan to supply an additional 50 million doses of Moderna's COVID-19 vaccine in 2022.
- 07/20/2021
|
New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from two final analyses from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE), which evaluated the long-term safety (primary endpoint) and efficacy of TAKHZYRO® (lanadelumab) 300 mg every two weeks for up to 2.5 years. In the first analysis, the mean (min, max) reduction in the attack rate compared to baseline observed in the
- 07/10/2021
|
European Patient Survey finds Crohn's Disease Patients Living with Perianal Fistulas Experience a More Significant Negative Impact on Their Quality of Life than Crohn's Disease Patients without Perianal Fistulas
- ZURICH & BRUSSELS--(BUSINESS WIRE)--The European Federation of Crohn's and Ulcerative Colitis Associations (“EFCCA”) in collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) today announced results from one of the largest of its kind self-reported patient surveys, exploring the health-related and overall real-world impact of perianal fistulas on the quality of life of people with Crohn's disease (CD), compared to the impact of CD without perianal fistulas.1,2,3,4,5,6 The survey fo
- 07/09/2021
|
Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
- Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
- 06/30/2021
|
Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community
- DUBAI, UAE, June 9, 2021 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) has introduced the "In Their Shoes" platform, an award-winning, immersive simulation program to promote greater awareness and empathy for patients with Inflammatory bowel disease (IBD), a condition to describe Crohn's disease and ulcerative colitis, to a group of healthcare providers in the Middle East the first time. The subscription-based program launched with a two-day simulation where healthcare providers and Takeda employees learned about the condition most effectively and profoundly: by "living with it.
- 06/09/2021
|
Losers Outnumber Gainers in Biotech IPOs This Year
- Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.
- 06/01/2021
|
Takeda's Dengue Vaccine Effective In Reducing Hospitalization Regardless Of Prior Infection
- Takeda Pharmaceutical Co Ltd (NYSE: TAK) unveiled long-term data for its dengue vaccine candidate (TAK-003), showing the shot's efficacy waned over time but that it was still “robust” in preventing hospitalization. The two-dose vaccine was 62% effective at preventing dengue infection three years after participants received the second dose, the latest data show.
- 05/24/2021
|
Potential Impact of Takeda's Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual's previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. TIDES
- 05/22/2021
|
Takeda's Maribavir US Application For Post-Transplant CMV Infection Under Review
- The FDA has accepted for review Takeda Pharmaceutical Co Ltd's (NYSE TAK) marketing application for maribavir for cytomegalovirus (CMV) Infection. The application under priority review is seeking maribavir approval CMV infection in those that are refractory with or without resistance (R/R), in solid organ transplant (SOT), or hematopoietic cell transplant (HCT) recipients.
- 05/21/2021
|
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) has accepted a New Drug Application (NDA) for maribavir for the treatment of CMV infection in those that are refractory with or without resistance (R/R), in solid organ transplant (SOT) or hematopoietic cell transplant (HCT) recipients. This is an inflection year for Takeda's pipeline with up
- 05/21/2021
|
Takeda Announces Approval of Moderna's COVID-19 Vaccine in Japan
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under article 14-3 of the Pharmaceuticals and Medical Devices Act for emergency use of Moderna's mRNA COVID-19 vaccine, TAK-919, now known as COVID-19 Vaccine Moderna Intramuscular Injection, in Japan. The approval is based on positive clinical data from Takeda's Phase 1/2 immunogenicity and safety cli
- 05/21/2021
|
Takeda CEO Says 2021 an 'Inflection Point' for Company
- Takeda Pharmaceuticals Inc. ( TAK , Financial) has cleared the decks and sees smoother sailing ahead. That's according to the Japanese company's CEO, Christophe Weber.
- 05/20/2021
|
Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that primary analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 57th American Society of Clinical Oncology (ASCO) Annual Meeting, and as an oral session at the virtual 26th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is a randomized, open-label study
- 05/19/2021
|
Takeda Pharmaceutical Company Limited's (TAK) CEO Christophe Weber on Q4 2020 Results - Earnings Call Transcript
- Takeda Pharmaceutical Company Limited's (TAK) CEO Christophe Weber on Q4 2020 Results - Earnings Call Transcript
- 05/11/2021
|
Takeda says it may double imports of Moderna shots to help accelerate Japan vaccination
- Takeda Pharmaceutical Co on Tuesday said it may double imports of Moderna Inc's COVID-19 vaccine to help Japan speed up COVID-19 inoculation efforts that have trailed most wealthy countries.
- 05/11/2021
|
Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced financial results for fiscal year 2020 (period ended March 31, 2021). TAKEDA PRESIDENT AND CHIEF EXECUTIVE OFFICER CHRISTOPHE WEBER commented: “Over the course of FY2020, Takeda remained resilient as we operated in new ways through the COVID-19 pandemic. This is a testament to the dedication of our employees, and Takeda's unwavering commitment to serving patients, our people,
- 05/11/2021
|
Moving Average Crossover Alert: Takeda Pharmaceutical (TAK)
- Takeda Pharmaceutical (TAK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- 05/03/2021
|
Takeda: A Rare Biopharma Bargain
- Takeda is one of the top ten biopharma companies worldwide in terms of revenue, and the number one in Asia.
- 05/02/2021
|
Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer
- CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company's New Drug Application (NDA) for mobocertinib (TAK-788) for the treatment of adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC), as detected by an FDA-approved test, w
- 04/27/2021
|
Down Nearly 50% From All-Time Highs, Is This Pharma Giant a Good Buy?
- You might want to consider adding this company to your portfolio.
- 04/24/2021
|
Coursera, Lattice Semiconductors, Qualcomm and More Monday Afternoon Analyst Calls
- With the trading day about halfway over, the broad markets were pulling back after setting record highs to close out last week.
- 04/19/2021
|
Larry Robbins' Firm Jumps Into Longview Acquisition Corp
- Larry Robbins ( Trades , Portfolio )'s firm has revealed a new buy into Longview Acquisition Corp. II (NYSE:LGV.U) according to GuruFocus' Real-Time Picks, a Premium feature.
- 04/05/2021
|
Why Molecular Templates Stock Crashed Today
- The company is taking back rights to one drug candidate and discontinuing development of another.
- 04/05/2021
|
ARK Genomic Revolution Multi-Sector ETF: Poised For Continued Underperformance
- ARK Genomic Revolution Multi-Sector ETF: Poised For Continued Underperformance
- 04/02/2021
|
Takeda Hosts Wave 1 Pipeline Market Call
- CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide updates on select New Molecular Entities (NMEs) in its Wave 1 pipeline portfolio. With several NME regulatory filings expected by year-end FY2021, the company will outline plans for organic and sustainable revenue growth over the next several years. Date April 6, 2021 Time 8:00 a.m. – 10:30 a.m. ET
- 04/01/2021
|
Takeda: Why Now Is The Time For Taking The Opportunity For Getting On The Takeda A-Train
- Takeda: Why Now Is The Time For Taking The Opportunity For Getting On The Takeda A-Train
- 04/01/2021
|
Takeda Is A Mediocre Income Investment
- Takeda is a Japanese healthcare company that pays consistent dividends. The company is trying to achieve growth using acquisition and research, and so far fails.
- 03/31/2021
|
Takeda Completes Sale of Its Japan Consumer Health Care Business Unit to Blackstone
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of Takeda Consumer Healthcare Company Limited (“TCHC”) to Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group Inc. and its affiliates (collectively “Blackstone”) for a total value of JPY 242.0 billion1. This divestment agreement was first announced in August 2020. Following the transfer of shares, TCHC wi
- 03/31/2021
|
Takeda, BridGene To Pursue Undruggable Neurodegenerative Targets
- Takeda Pharmaceutical Co Ltd (NYSE: TAK) has teamed up with BridGene Biosciences to discover small molecules against hard-to-drug therapeutic targets. The deal will utilize BridGene's IMTAC Chemoproteomics platform to identify targets and small molecule drug candidates for Takeda to take into clinical development.
- 03/30/2021
|
Alibaba, Amazon, Palantir, Google, Takeda, Unity — What Cathie Wood's Ark Bought And Sold On Thursday
- Cathie Wood's Ark Investment Management sends out an email every night listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have known to cause certain stocks to see a spike in the after-hours session.
- 03/26/2021
|
Anima Attracts Takeda In Multibillion-Dollar mRNA Translation Modulators Deal For Neurological Diseases
- Small-molecule mRNA translation Israeli firm Anima Biotech Inc has landed a new research deal with Takeda Pharmaceutical Co Ltd (NYSE: TAK), covering as many as six programs for genetically-defined neurological diseases. Two-part collaboration could hold as much as $2.3 billion in clinical and commercial milestone payouts.
- 03/18/2021
|
Larry Robbins' Firm Buys Into HighCape Capital Acquisition
- Larry Robbins ( Trades , Portfolio )'s firm has revealed a new buy into HighCape Capital Acquisition Corp. (NASDAQ:CAPA) according to GuruFocus' Real-Time Picks, a Premium feature.
- 03/16/2021
|
IDT Biologika To Make J&J's COVID-19 Vaccine Using Takeda's Manufacturing Capacity
- Japan's Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson's (NYSE: JNJ) single-dose COVID-19 vaccine. Under the contract, the capacity at IDT's Dessau site, previously reserved to make Takeda's dengue vaccine candidate, will be used to make J&J's COVID-19 vaccine for worldwide distribution.
- 03/15/2021
|
Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance)
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today during the Presidential Symposium at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) announced the results from a subgroup analysis of the Phase 3 TAK-620-303 (SOLSTICE) trial, for the investigational drug TAK-620 (maribavir), which supported the efficacy results from the overall randomized population. More than three times as many (62.8%; 76/121)
- 03/15/2021
|
Takeda and IDT Support Manufacturing of Johnson & Johnson's COVID-19 Vaccine
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda's dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. At the end of a three-month period, the capacity will be
- 03/15/2021
|
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
- 03/12/2021
|
Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio
- OSAKA, Japan & BRISBANE, Calif.--(BUSINESS WIRE)--Takeda exercised its option to acquire Maverick, expanding its immuno-oncology portfolio with two development candidates and a T-cell engager platform
- 03/09/2021
|
Finch Therapeutics Takes Flight With IPO Plan
- Finch Therapeutics Takes Flight With IPO Plan
- 03/08/2021
|
Moderna, via Takeda, seeks authorization for COVID-19 vaccine in Japan
- Shares of Moderna Inc. were down 0.9% in premarket trading on Friday after the company said it is pursuing approval for its COVID-19 vaccine in Japan in partnership with Takeda Pharmaceutical Co. . Takeda submitted the new drug application and will be tasked with importing and distributing the vaccine from the Cambridge, Mass.
- 03/05/2021
|
Takeda Seeks Approval For Moderna's COVID-19 Shot In Japan
- Takeda Pharmaceutical Co Ltd (NYSE: TAK) has asked regulators to approve the use of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine (mRNA-1273 or TAK-919). Takeda filed the New Drug Application to import and distribute the shot.
- 03/05/2021
|
Moderna Announces New Drug Application Submitted to Import and Distribute Moderna's COVID-19 Vaccine Candidate in Japan
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces New Drug Application submitted to import and distribute Moderna's COVID-19 vaccine candidate in Japan.
- 03/05/2021
|
Ovid Shares Rally On Soticlestat Development Pact With Takeda In Rare Epilepsy Syndromes
- Takeda Pharmaceutical Co Ltd (NYSSE: TAK) has agreed to secure global rights from Ovid Therapeutics Inc (NASDAQ: OVID) for soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). Under this new agreement, Takeda will develop and commercialize soticlestat globally, and Ovid will no longer have any financial obligation to Takeda under the original collaboration agreement announced in 2017.
- 03/03/2021
|
The Top New Buys of Larry Robbins' Firm
- Glenview Capital Management recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.
- 02/26/2021
|
Takeda Divests Four Diabetes Products In Japan To Teijin Pharma
- Takeda Pharmaceutical Co Ltd (NYSE: TAK) will sell its four non-core type-2 diabetes products (Nesina, Liovel, Inisync, and Zafatek) in Japan to Teijin Pharma Limited, ¥133 billion (roughly $1.25 billion). The portfolio generated total sales of approximately ¥30.8 billion (roughly $290 million) in FY2019.
- 02/26/2021
|
Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to transfer the assets, marketing rights and, eventually, marketing authorization associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited (“Teijin Pharma”), a Tokyo-based pharmaceutical company, for JPY 133.0 billion, subject to customary legal and regulatory closing conditions. The portfolio to be diveste
- 02/26/2021
|
Prometheus Biosciences Starts $125 Million IPO Plan
- Prometheus Biosciences Starts $125 Million IPO Plan
- 02/25/2021
|
BioLife Plasma Services Announces Expansion of Plasma Donation Centers Into California
- MORENO VALLEY, Calif.--(BUSINESS WIRE)--BioLife Plasma Services announces expansion of plasma donation centers into California.
- 02/24/2021
|
Takeda Doses First Participant In Novavax COVID-19 Vaccine Study In Japan
- Takeda Pharmaceutical Co Ltd (NYSE: TAK) said that the first patient had been dosed with Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine candidate (dubbed as TAK-019) in a Japanese clinical trial. The first volunteer was given a Novavax shot in a Phase 1/2 immunogenicity and safety trial of 200 adult volunteers in Japan.
- 02/24/2021
|
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax' and Moderna's COVID-19 Vaccine Candidates in Japan
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax' COVID-19 vaccine candidate (TAK-019) in Japan. Earlier this month, Takeda completed enrollment in the company's Phase 1/2 immunogenicity and safety study of Moderna's COVID-19 vaccine candidate (TAK-919) in Japan. “Early in the pandemic, we made the decision to partner with other companies and lever
- 02/24/2021
|
ARKG: Precautionary Measures, But Transformational Objectives Remain Intact
- Cathie Wood and her team have shown investors that they have the capability to turn double-digit growth dreams into reality.
- 02/22/2021
|
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 02/19/2021
|
Takeda Receives Prestigious EURORDIS 2021 Black Pearl Award for Patient Engagement
- ZURICH--(BUSINESS WIRE)-- #EURORDISAwards2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) Takeda has been announced the winner of the EURORDIS 2021 Award for Patient Engagement in recognition of the company's unwavering commitment to rare disease patients and its comprehensive partnerships with the rare disease patient community. The annual EURORDIS Black Pearl awards ceremony is a celebration of achievements and exceptional work in this space and is held every February marking Rare Disease
- 02/18/2021
|
Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/Disease
- OSAKA, Japan--(BUSINESS WIRE)--Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint
- 02/12/2021
|
Takeda Files Japan Marketing Application For Darvadstrocel In Crohn's Disease
- Takeda Pharmaceutical Co Ltd (NYSE: TAK) has applied to the Japanese regulatory authority seeking approval for Darvadstrocel (Cx601) to treat complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease. Darvadstrocel received an orphan drug designation in Japan in March 2019.
- 02/10/2021
|
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn's Disease
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (development code: Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease (CD). The application filing included data from two trials, the Japanese Study Darvadstrocel-3002 and the
- 02/10/2021
|
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q3 2021 Results - Earnings Call Transcript
- Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q3 2021 Results - Earnings Call Transcript
- 02/05/2021
|
Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended December 31, 2020). TAKEDA CHIEF FINANCIAL OFFICER COSTA SAROUKOS commented: “Our third-quarter results demonstrate the resilience of our business model and the depth of our portfolio, with strong growth generated by our 14 global brands. As a values-based and R&D driven biopharmaceutical company, we r
- 02/04/2021
|
Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements
- OSAKA, Japan--(BUSINESS WIRE)--Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements
- 02/03/2021
|
Takeda Completes Sale of TachoSil® to Corza Health
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil® Fibrin Sealant Patch (“TachoSil®”) to Corza Health, Inc. (“Corza”) for €350 million. TachoSil® is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control. Under the terms of the transaction, Corza has acquired the assets and licenses that support the development
- 02/01/2021
|
Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products sold in Latin America to Hypera S.A. (“Hypera Pharma”) for a total value of $825 million USD. This divestment agreement was first announced in March 2020. The divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, and other South American,
- 01/29/2021
|
Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy
- CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in previously treated patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC) will be presented as a late-breaking oral session at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference o
- 01/28/2021
|
Takeda Achieved Carbon Neutrality in 2020
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it achieved carbon neutrality in its value chain for its fiscal year 2019. This achievement was delivered by a continued focus on internal energy conservation measures, procurement of green energy, and investment in renewable energy certificates and high-quality, verified carbon offsets. These actions collectively address 100 percent of Takeda's fiscal year 2019 scope 1, 2, a
- 01/27/2021
|
Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D ca
- 01/26/2021
|
Takeda Named Global Top Employer for Fourth Consecutive Year
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is one of only 16 companies to achieve global Top Employer® certification for 2021. In addition to receiving the global certification for the fourth consecutive year, Takeda was also certified as a Top Employer in four regions and 38 countries. This underscores the company's commitment to creating an exceptional people experience for its global workforce
- 01/24/2021
|
Takeda's Entyvio SC and Celltrion's Remsima SC EU5 Launches Have Benefitted from Parent Brand Reputation, New Clinical Data, and COVID-19 Restraints, According to Spherix Global Insights
- EXTON, Pa., Jan. 20, 2021 /PRNewswire/ -- Two 2020 European Medical Agency (EMA) approvals, Takeda's Entyvio SC and Celltrion Healthcare's infliximab biosimilar, Remsima SC, have captured notable shares among EU5 IBD patients, according to Spherix's recent report, RealTime Dynamix™:...
- 01/20/2021
|
The Stocks That 3 Japan-Centered Gurus Agree On
- According to the Aggregated Portfolio of Gurus, a Premium feature of GuruFocus, the Hennessy Japan Fund (Trades, Portfolio), the T. Rowe Price Japan Fund (Trades, Portfolio) and the Matthews Japan Fund (Trades, Portfolio) have several stocks in common.
- 01/14/2021
|
Takeda Provides Pipeline Update and Shares Goal to Increase Revenue 50% by FY2030 at the 39th Annual J.P. Morgan Healthcare Conference
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on the progress of its continued transformation and growth today at the virtual 39th Annual J.P. Morgan Healthcare Conference. President and Chief Executive Officer, Christophe Weber, shared details on Takeda's portfolio and pipeline strategy and financial outlook, including key programs expected to contribute to the company's revenue growth over the next dec
- 01/11/2021
|
Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference
- OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:20 p.m. ET on Monday, January 11, 2021 / 7:20 a.m. JT on Tuesday, January 12, 2021. Investors and the general public are invited to listen to the live webcast with Christophe Weber, president and chief executive officer, here. A replay of the webcast will also be archived at the same location. A
- 01/11/2021
|
3 Low Price-Book Ratio Stock Picks
- Screening the market for securities whose market capitalization surpasses $2 billion and whose price-book ratios are trading below 1.5 could yield a higher likelihood of unearthing value opportunities, in my view.
- 01/10/2021
|
Takeda Completes Sale of Select Non-Core Assets to Cheplapharm
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD1. The portfolio includes 16 prescription pharmaceutical products sold predominantly in Europe which is part of Takeda's Europe and Canada Business Unit. This divestment agreement was first announced in September 2020. The divested port
- 01/05/2021
|
Seagen Earns Top Honors from Key Biotech Publication
- Seagen, Inc. (SGEN) has recently been named Biotech of the Year by leading industry publication Biopharma Dive, and investors would no doubt agree. Shares of the Seattle-area firm are up nearly 65% year-to-date, far outpacing the Nasdaq Biotechnology Index, which has climbed about 28% since the beginning of the year.
- 12/31/2020
|
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (China) (“Hasten”), a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited (“Ray Capital”)1 Takeda will receive $322 million USD, subject to customary legal and regulatory c
- 12/21/2020
|
U.S. FDA Approves Supplemental New Drug Application for Takeda's ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML
- CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) for adult patients with chronic-phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors. The updated label includes an optimized, response-based ICLUSIG dosing regimen in CP-CML with a d
- 12/18/2020
|
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda's TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) and granted Priority Review for the investigational therapy budesonide oral suspension, TAK-721, which has been designed specifically for eosinophilic esophagitis (EoE).1 If approved, TAK-721 will be the first FDA-approved treatment for the chronic infl
- 12/15/2020
|
Japan's Takeda says drug pipeline to lift sales to $48 billion in next decade
- Japan's Takeda Pharmaceutical Co said on Wednesday its drug pipeline is poised to drive annual sales up by more than 50%, to 5 trillion yen ($48.01 billion) in the next decade.
- 12/08/2020
|
Takeda's Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade
- OSAKA, Japan--(BUSINESS WIRE)--As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on its pipeline portfolio, which has the potential to contribute significantly to revenue growth for the company over the next decade. The company also shared its PTS adjusted2 view for FY2019-FY2030 revenue CAGR (low single-digit), as well as its goal for FY2019-FY2030 revenue CAGR (mid-single-digit), amounting to JPY5 tr
- 12/08/2020
|
Takeda Further Enables Hemophilia A Personalized Care With Launch of myPKFiT® Software for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated]
- CAMBRIDGE, Mass. and OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. availability of myPKFiT® for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated], a web-based software and mobile application that is the first and only pharmacokinetic (PK)-dosing software approved by the U.S. Food and Drug Administration (FDA) for hemophilia A patients 12 and older and weighing at least 29 kg treated with ADYNOVATE.1 The myP
- 12/02/2020
|
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”) for a total value of $278 million USD inclusive of milestone payments. The portfolio includes 18 pharmaceutical products and over-the-counter (OTC) products sold in Asia Pacific, which is part of Takeda's Growth & Emerging Markets Business Unit. This divestment agr
- 11/30/2020
|
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
- THOUSAND OAKS, Calif., Nov. 30, 2020 /PRNewswire/ -- Three members of the COVID R&D Alliance - Amgen Inc. (NASDAQ: AMGN), Takeda Pharmaceutical Co. Ltd. (NYSE: TAK), and UCB (Euronext BR: UCB) - today announced the first patient enrolled in the COMMUNITY Trial (COVID-19 Multiple Agents...
- 11/30/2020
|
Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in Research Alliance with Takeda
- PARIS--(BUSINESS WIRE)--Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”). In the course of the strategic research alliance that was announced in June 2020, Egle will validate novel tumor-infil
- 11/26/2020
|
Takeda Pharma's Venkayya on Global Race for Covid Vaccines
- Nov.22 -- Rajeev Venkayya, president of the global vaccine business unit of Japan's Takeda Pharmaceutical Co., discusses the latest developments in the global race for Covid-19 vaccines. The company said last month it will import and distribute Moderna Inc.'s Covid-19 vaccine candidate starting in the first half of 2021.
- 11/23/2020
|
Which Coronavirus Vaccine Maker Is Poised to Be the Top Supplier?
- The numbers are close, but two players stand out at the moment.
- 11/14/2020
|
Japan's Takeda eyes new focus on vaccines after OTC asset sales: CEO
- Japan's Takeda Pharmaceutical Co is looking at making vaccines a core business after completing asset sales to lower debt following its takeover of Shire Plc, Chief Executive Christophe Weber said.
- 11/05/2020
|
Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting
- CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present 22 company-sponsored abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting, being held virtually December 5-8, 2020. The company's scientific research at ASH will identify unique approaches in advancing the treatment of hematologic cancers, illustrative of its commitment to developing and providing transformative solution
- 11/05/2020
|
Kamada Looks Cheap AS Takeda Deal Creates Value
- We believe Kamada looks cheap, as there are long-tailed asset returns from the Takeda deal which the market may be overlooking. Recent retraction in Kamada's shares on the charts signals a potential dislocation in value and to today's trading.
- 11/02/2020
|
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q2 2021 Results - Earnings Call Transcript
- Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q2 2021 Results - Earnings Call Transcript
- 10/30/2020
|
Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first half of fiscal year 2020 (period ended September 30, 2020). TAKEDA PRESIDENT & CHIEF EXECUTIVE OFFICER CHRISTOPHE WEBER commented: “Takeda's performance in the first half of FY2020 demonstrates the resilience of our business model, the depth of our portfolio and the commitment of our employees, who continue to serve patients and communities glob
- 10/29/2020
|
Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan
- OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), announced today that it will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. This effort is part of a three-way agreement among Takeda, Moderna and the Government of Japan's Ministry of Health Labour and Welfare (MHLW). Moderna has previously announced that the 30,000 participant Phase 3 clinical tria
- 10/29/2020
|
Takeda Presents Rare Bleeding Disorders Research at Thrombosis & Hemostasis Summit of North America (THSNA) 2020
- CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented four abstracts at the Thrombosis and Hemostasis Summit of North America (THSNA), highlighting Takeda's commitment to advancing personalized care in people living with bleeding disorders. These studies may help provide further data to healthcare providers regarding treatment personalization in patients with hemophilia and von Willebrand's disease (VWD). “When l
- 10/27/2020
|
